Key Takeaways
- PAT milestone hit, but FY23 is a deliberate consolidation year: FY22 PAT crossed Rs. 100 Crores, a target set three years ago, yet management guided for only 5% to 10% growth in FY23, citing a need to consolidate after a year of huge growth and factoring in US inflation.
- Lab grown diamonds are the margin and mix story: Lab grown jewellery already contributes 20% of revenue, and management expects it to reach 25% in FY23 and over 50% within three years, a shift they say will lift EBITDA margins close to 25%.
- A major customer win de-risks the capacity build: The company was empaneled last week with the world's largest jewellery retailer for lab grown diamond jewellery, and all additional product from the new Rs. 10 crore CAPEX is already spoken for with confirmed off-take.
- Supply chain costs hit the quarter but are being passed through: Q4 gross margin compressed because Russian sanctions forced higher raw material procurement costs, though the company has since successfully passed these increases on to customers.
- What to watch next quarter: Whether the new lab grown capacity ramps up on schedule in Q1 FY23, the pace of the margin recovery as raw material costs are passed through, and any concrete progress on the B2C India evaluation or an acquisition for distribution.
Lab Grown Diamond Strategy & Margins
- Mix shift underway: Lab grown diamond jewellery is 20% of overall revenue, with a focus on large carat stones in the engagement and wedding category where average selling prices exceed $1,000, versus $500 for natural diamond jewellery.
- Margin protection via integration: The company is fully integrated from growing diamonds to cutting to jewellery manufacturing to distribution, capturing margin at every point in the supply chain rather than only on the finished piece.
- Technology moat: Two years of R&D produced a formula to grow diamonds consistently month-on-month at a commercialized rate, and a perpetual license for four US patents provides easy reach to US retailers.
- Capacity doubling on the horizon: Management is evaluating a roadmap to double lab grown diamond capacity in the coming two years, with an additional Rs. 10 crores to Rs. 35-40 crores in CAPEX possible within the next 12 months.
- End-market validation: The company was empaneled last week with the world's largest jewellery retailer for lab grown diamond jewellery, and its five large existing customers each have the capability to buy between $5 million and $50 million individually.
Rashesh Bhansali: "We are actually expecting lab grown diamonds to grow very strongly. So, I can say that in FY23, we may look at 25% of the overall business and within three years we expect it to be more than 50% of Goldiam."
FY23 Outlook & Consolidation
- Deliberate slowdown: Management guided for 5% to 10% growth in FY23, characterizing it as a year of consolidation after a period of huge growth, with US inflation adding caution.
- Base business trajectory: The natural diamond and other legacy business is expected to grow at a 5% to 10% CAGR over three years.
- Post-consolidation acceleration: After the FY23 consolidation year, management expects growth to re-accelerate to 15% to 20%.
- Order book visibility: An order book of more than Rs. 150 crores is expected to be executed within the next few months, though July is when larger seasonal orders typically arrive.
- Geographic focus: The US remains the top priority, with Australia seen as the most similar market and a natural next step; Europe is not a target because its jewellery uses smaller diamonds and has a different look and feel.
Rashesh Bhansali: "And since we have come out from a year of a huge growth, we are looking for a year of consolidation to a modest 5% to 10% growth for the existing year."
Margin Structure & Profitability
- Q4 gross margin pressure: Supply chain constraints from the ALROSA problem and Russian sanctions forced higher procurement costs for raw material, compressing gross margin in the quarter.
- Cost pass-through executed: The company has successfully passed on the increase in raw material prices to customers, suggesting the margin pressure is temporary.
- EBITDA target tied to mix: If lab grown diamonds reach 50% of the business, management expects EBITDA to move close to 25%, up from current levels.
- Power cost tailwind: SEEPZ power costs have already reduced from Rs. 12-13 per unit to Rs. 9 per unit, and management is hopeful of a further reduction to Rs. 7 per unit by September based on government interactions.
- ROE transformation: ROE improved to 22% in FY22 from 15% in FY21 and 6% in FY18, while ROCE reached 60% in FY22 from 10.6% in FY18, driven by the asset-light, design-based model and lab grown focus.
Rashesh Bhansali: "If lab grown diamonds become 50% of our business, EBITDA will definitely move close to 25%."
Working Capital & Supply Chain
- Negative operating cash flow explained: OCF turned negative by Rs. 15-10 crores versus Rs. 50 crores positive last year, driven entirely by an inventory build-up to avoid supply chain disruptions and to support e-commerce guaranteed delivery of 5-7 days.
- E-commerce as a working capital hedge: 15% of the business is e-commerce operating on negative working capital, which helps reduce overall working capital days, and management targets growing this to 25% within the next few years.
- Raw material buffer: The company has bought enough raw materials for the next two to three months to house orders, and management expects supply chain pressure will not repeat.
- Receivables focus: The company is working with clients to get payments within 90-120 days and with some wholesalers from 120-150 days, aiming to reduce working capital days further.
Competitive Positioning & Market Structure
- India's structural advantage: India cuts and polishes 85-90% of the world's mined diamonds and almost the entire lab grown production, and FTA agreements with Australia and the UK are expected to help Indian manufacturers take market share from China and Thailand.
- Backward integration as a differentiator: Management claims Goldiam is probably the only listed company with 100% backward integration from diamond growing to finished jewellery, capturing the entire value chain's profitability.
- Nascent industry, opaque data: When asked to name competitors doing $20 million in lab grown diamonds globally, management deflected, stating the industry is nascent with no council or government figures available, and only cited the American lab grown retail figure of roughly $4 billion.
- Retailer strategy varies: Different US retailers are introducing lab grown diamonds at varying degrees of scale, and Goldiam is positioning itself as the number one vendor providing an end-to-end integrated solution.
Anmol Bhansali: "We basically see different retailers playing their strategy as to how they want to introduce lab grown diamonds, it is definitely without a doubt in the US become a category that every retailer needs to have at varying degrees of skill and the Goldiam is striving to be the number one vendor or the number one supplier that can provide an end to end integrated solution for these retailers."
Capital Allocation & Shareholder Returns
- Dividend policy formalized: The board passed a policy of distributing a minimum of 50% of standalone profits as dividends or buybacks.
- CAPEX underway: Rs. 10 crores is being deployed to enhance in-house lab grown diamond capacity, adding 30% to 35% capacity, with commercial production starting in Q1 FY23 and all additional product already spoken for.
- Inorganic growth still on the radar: The company is still looking for an acquisition that helps in distribution, and management noted that valuations coming off slightly will only help going forward, though no right fit has been found yet.
- B2C India exploration: Management is evaluating opportunities to enter the B2C business in India with lab grown diamonds and could look into investing in the upcoming year, believing the category will grow dramatically once the Indian public understands it.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue growth | 5% to 10% overall growth (year of consolidation) | FY23 |
| Lab grown revenue mix | 25% of overall business | FY23 |
| Lab grown revenue mix | More than 50% of Goldiam | Within three years |
| EBITDA margin | Move close to 25% | When lab grown becomes 50% of business |
| Lab grown capacity addition | Rs. 10 crores CAPEX, 35% to 40% capacity increase, commercial production | Q1 FY23 |
| Additional lab grown CAPEX | Rs. 10 crores to 35-40 crores | Within next 12 months |
| Post-consolidation growth | 15% to 20% growth | After FY23 consolidation year |
| Base business (ex-lab grown) growth | 5% to 10% | Over three years |
| Shareholder distributions | Minimum 50% of standalone profits via dividends or buybacks (buybacks not forward-looking) | Ongoing policy |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| PAT (full year) | ₹100 cr+, milestone surpassed for FY22 |
| Revenue growth guidance (FY23) | 5% to 10%, year of consolidation after high growth |
| EBITDA margin | 21%–22%, full year at 22% |
| Order book | ₹150 cr+, expected execution in next few months |
| Lab grown diamond revenue share | 20% of overall revenue |
| Lab grown diamond revenue share target (FY23) | 25% of overall business |
| Lab grown diamond revenue share target (3 years) | more than 50% of Goldiam |
| E-commerce revenue share | 15% of business |
| E-commerce revenue share target (few years) | 25% of business |
| ROE (full year) | 22%, up from 15% in FY21 and 6% in FY18 |
| ROCE (full year) | 60%, improved from 10.6% in FY18 |
| Cash and cash equivalents | ₹200 cr as of date |
| Lab grown diamond capacity addition (May 2022) | 30% to 35% additional capacity, reaching over 650 polished carats per month |
| Lab grown diamond ASP premium over natural | 120% premium over mined diamond jewelry |
| Natural diamond jewelry ASP | $500 |
| Lab grown diamond jewelry ASP | over $1,000 |
| Lab grown diamond captive consumption | more than 85% of growing used for own jewellery orders |
| US lab grown diamond retail market size | $4 bn |
| Goldiam lab grown diamond revenue (last year) | $20 mn |
| Base business (ex-lab grown) growth guidance (FY23) | 5% to 10% |
| Base business growth guidance (3-year CAGR) | 5% to 10% |
| Post-FY23 growth guidance | 15% to 20% |
| Dividend distribution policy | 50% minimum of standalone profits, via dividends or buybacks |
| Power cost per unit | ₹9, reduced from ₹12–13 |
| Planned additional CAPEX (next 12 months) | ₹10 cr to ₹35–40 cr for lab grown diamond capacity |
| Q4 gross margin pressure driver | Raw material cost increase due to ALROSA supply constraints and Russian sanctions |
| OCF after working capital | (-)₹15–10 cr, vs ₹50 cr last year, driven by inventory build |